business for Good you fourth and joining afternoon and year-end update. quarter our thank earnings call and
Lisa Financial and call available Officer; on have us me this are Chief Lisa Medical Trevi's of Trevi's today remarks, Officer. Dr. and for prepared Chief I David some X then Clark, Joining Delfini, questions. the be will
our XXXX both the with we company well IPF regard mechanism reading left us on best out was unique cough strong space, that our to lack of drug, for strength grow for our therapy IPF utility With the out positive, carve to Haduvio. it position broad and as stakeholders. to a data in transformational the a IPF. as decide how strong for a of of trials feel in year can Based and we nodularis in cough validating competition the the position prurigo Trevi in of the and
central that disease is. therapy the and believe the of we underlying the of regardless what a mechanism because also chronic drug, of range potential of our We across peripheral provide differentiated have to cough indications
now buckled next focused decisions those the in and and we strong in with made are executing raising So development. plans against capital on of stage for our XXXX,
disease the It of quality chronic coughing. is IPF significantly XX% programs, suffering program each chronic cause is update provide with starting that to our a and cough is patient's an impacting a cough IPF. in up morbidity, now major and me are life. our chronic patients of IPF from of estimated on serious end-of-life Let lead of
refractory chronic next from trials development cough. indication, in for in can take there prepare the learnings work many As we occurring this we our are
there related underlying of a the IPF to we frail However, population on aspects the but need are disease in that patient mind. to this only also effect in population keep not safety unique also potential patient
We in in parallel phase cough studies IPF development program. next of our are chronic conduct planning during to X this
dropped dose-ranging The The we a are will we will study in XX, the X BID. IIb minimally of lower the very highest at be are first dose trial data and that it study, to from study the early II Because as Phase Phase trial these that to XXX occurred is doses doses. the patients, Based important doses. understand efficacy illness of have planning XX severity appears on and it dose. the the CANAL in the milligrams effective
for We approximately dosing for arm weeks. are total XXX end approximately per X planning a of for study and XX the in subjects
be on study planning are We to countries in to conducting multiple complete a able enrollment in this manner. timely
give enrollment on will study. time we lines guidance once the better We initiate
In a planning parallel, study. respiratory physiology Ib we Phase are for
our across regarding clinically to lung an patients to pivotal of studies our is to These determine to know, may with But varying early. IPF and depression. we inpatient have data depression. in our not respiratory patients, this study important box feel we class impairment population X impact question you Haduvio seen in something We a in define if various respiratory warning because black all help dose the doses optimal run and study plan As severity the significant have is in This increasing we of program. IPF will an a doses the levels safety disease patient on label or of opioids studies see date.
are the to protocol physiology awaiting respiratory the their submitted have FDA We and feedback.
called EU a in preparing reviews submissions new trials. the to is parallel. mandatory process, CTIS XXXX. support authority There new and perform We became in Europe ethics these and of January in the the health U.K. also committees for regulatory their which the Under XX, the are as process
As process will although is little how the a is process, the there and growing result, there's going pains. will streamline more new show theory, submission. expect this upfront data to review to information be there the required make implementation companies In
new informed So makes is make play expected we to estimate. aware lines will I keep you you which time of lines there time but our wanted difficult to in a process
can have clinical and an team agreement our is on regulatory so the IND. initiate studies operations we for open we parallel, preparing In these that protocol once
will overall We we estimated half of trial initiate IPF design for second the the provide timing expect well to both of on begin as the the studies once final in XXXX the studies. guidance we and these as
only preparations the developing and chronic will cough, a establish refractory to look in In a refractory Phase protocol this PXXXs. That peripherally also trial study are in has the like for PXXXs IPF in lung. successful, will with lot have a to proof-of-concept seek addition lot one in which mechanism study. cough we There the the a chronic condition, been II CANAL of been trials work cough.
in is RCC a works broader to and the strong set in the for in believe has brain a patients. there opportunity centrally we peripherally provide significant still lungs potential the both However, that of and consistent a and mechanism efficacy
presented to lot in has pulmonology. KOLs been by date generated at of respiratory data to has a meetings continued attention garner globally various and cough Our
data During the the Dr. British Society fourth Philip quarter, meeting. Thoracic Molyneaux at presented
Virginia of be on a meeting. American be through unique at and XX And manuscript CANAL Monday, the March is submitting on On we'll D.C., it We results meeting. presented there will be Annual publication for Conference, in at German and finalized June peripheral will at Thoracic trial XX be from in another Cough the Society on Washington, central American action broadly in shortly. results a it there X be will presentation our and why important the the presentation XX, could cough. and On have Reston, May additional mechanism also Pulmonology
been presentations. almost oral I our submissions important think it note have for to that is conference chosen all of
speaks to in this community's medical interest unmet we the and to importance think the the of address. our program are medical need I trying
treatment last and have debilitating where work we The severe June itching. the is in positive statistical PRISM nodularis, ongoing characterized we also is reported well PN. program PN The significance and which the of serious skin In or achieved year, of primary trial in on disease nodules endpoints. for data as incessant Phase secondary the and on other by as IIb/III the all and papules key a trial prurigo
and PRISM. an II end the this from second expect X-year have meeting to the open-label we FDA should prepare of receive the extension associated which that of During that we'll data with quarter for XXXX, Phase was first in the with quarter We the completed year. study we study
complete quarter U.S. butorphanol. the version in placebo-controlled nalbuphine this Finally, part selected One potential we characterizing human a with the nalbuphine studied in study The the the end objective abuse Agency, butorphanol The the double-blind, of data of top dose X study in second and The the commenced compare the by to from oral of of Drug liability The unscheduled of crossover the be X-way the This will year. XXXX. study abuse injectable butorphanol DEA. currently of last Schedule also by doses. to to currently various abuse is study is the a a to to of nalbuphine trial line Part oral fourth part or protocol active of relative butorphanol. parts, Butorphanol of randomized, expects conducted is company is is selected the dose be in drug. design. and Enforcement determine study the IV completing X first is potential
to get or progress and open-label working It at team conduct extension PN. his and initiate David a completing each is part a to process are studies critical time the and making X of right good This of separate Trevi these. busy against is in the
details initiate the each We study more we one. with will announce of as start each
the to and on team back XXXX, data by such our positioned trial financings proud and also diseases. interstitial as development am subsequent in continue chronic well lead the results extremely our look I in I RCC IPF indications. serious of but trial cough in The only cough of positive have Haduvio other the both conditions of chronic and cough us not As execution lung
with stage of Phase we of meeting development. end with help determine are potential discussions next this that FDA The to II advance For clinical into program will the next program. partners for the in PN, steps
over Lisa review turn to results, will our open to it will we for now up financial then I questions. it
